Literature DB >> 28980505

Clostridium difficile infection: new approaches to prevention, non-antimicrobial treatment, and stewardship.

Maria Adriana Cataldo1, Guido Granata1, Nicola Petrosillo1.   

Abstract

INTRODUCTION: Despite the large amount of scientific publications exploring the epidemiology and the clinical management of Clostridium difficile (CD) infection, some issues remain unsolved or need further studies. The aim of this review is to give an update on the hot topics on CD prevention, including stewardship programs, and on the non-microbiological treatment of CD infection. Areas covered: This article will review the importance of minimizing the CD spore shedding in the healthcare environment for potentially reducing CD transmission. Moreover, antimicrobial stewardship programs aimed to reduce CD incidence will be reviewed. Finally, new strategies for reducing CD infection recurrence will be described. Expert commentary: Besides the basic infection control and prevention practices, including hand hygiene, contact isolation and environmental cleaning, in the prevention of CD infection other issues should be addressed including minimizing the spread of CD in the healthcare setting, and implementing the best strategy for reducing CD infection occurrence, including tailored antimicrobial stewardship programs. Regarding new advancements in treatment and management of CDI episodes, non-antimicrobial approaches seem to be promising in reducing and managing recurrent CD infection.

Entities:  

Keywords:  Clostridium difficile; albumin; antimicrobial stewardship; immunity; infection prevention and control; microbiota; non-antimicrobial treatment

Mesh:

Substances:

Year:  2017        PMID: 28980505     DOI: 10.1080/14787210.2017.1387535

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  5 in total

1.  [Results of the Program for the Rational Use of Antimicrobials in a Mexican hospital, 2013-2018Resultados de um programa para o uso racional de antimicrobianos num hospital no México, 2013-2018].

Authors:  Oscar Sosa-Hernández; Claudia Vázquez-Zamora; Víctor Hugo Gutiérrez-Muñoz; Gustavo Esteban Lugo-Zamudio; Mónica Alethia Cureño-Díaz
Journal:  Rev Panam Salud Publica       Date:  2020-09-23

Review 2.  How Does COVID-19 Pandemic Impact on Incidence of Clostridioides difficile Infection and Exacerbation of Its Gastrointestinal Symptoms?

Authors:  Masoumeh Azimirad; Maryam Noori; Hamideh Raeisi; Abbas Yadegar; Shabnam Shahrokh; Hamid Asadzadeh Aghdaei; Enrico Bentivegna; Paolo Martelletti; Nicola Petrosillo; Mohammad Reza Zali
Journal:  Front Med (Lausanne)       Date:  2021-12-13

3.  The burden of Clostridioides difficile infection in COVID-19 patients: A systematic review and meta-analysis.

Authors:  Guido Granata; Nicola Petrosillo; Samir Al Moghazi; Emanuela Caraffa; Vincenzo Puro; Glenn Tillotson; Maria Adriana Cataldo
Journal:  Anaerobe       Date:  2021-11-26       Impact factor: 2.837

Review 4.  Novel Antimicrobials for the Treatment of Clostridium difficile Infection.

Authors:  Nicola Petrosillo; Guido Granata; Maria Adriana Cataldo
Journal:  Front Med (Lausanne)       Date:  2018-04-16

5.  Clinical impact of a Clostridioides (Clostridium) difficile bedside infectious disease stewardship intervention.

Authors:  María Olmedo; Maricela Valerio; Elena Reigadas; Mercedes Marín; Luis Alcalá; Patricia Muñoz; Emilio Bouza
Journal:  JAC Antimicrob Resist       Date:  2020-08-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.